Literature DB >> 31990323

In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study.

Christian Zanchin1, Yasushi Ueki1, Sylvain Losdat2, Gregor Fahrni3, Joost Daemen4, Anna S Ondracek5, Jonas D Häner1, Stefan Stortecky1, Tatsuhiko Otsuka1, George C M Siontis1, Fabio Rigamonti6, Maria Radu7, David Spirk8, Christoph Kaiser3, Thomas Engstrom7, Irene Lang5, Konstantinos C Koskinas1, Lorenz Räber1.   

Abstract

AIMS: We assessed morphological features of near-infrared spectroscopy (NIRS)-detected lipid-rich plaques (LRPs) by using optical coherence tomography (OCT) and intravascular ultrasound (IVUS). METHODS AND
RESULTS: IVUS-NIRS and OCT were performed in the two non-infarct-related arteries (non-IRAs) in patients undergoing percutaneous coronary intervention for treatment of an acute coronary syndrome. A lesion was defined as the 4 mm segment with the maximum amount of lipid core burden index (maxLCBI4mm) of each LRP detected by NIRS. We divided the lesions into three groups based on the maxLCBI4mm value: <250, 250-399, and ≥400. OCT analysis and IVUS analysis were performed blinded for NIRS. We measured fibrous cap thickness (FCT) by using a semi-automated method. A total of 104 patients underwent multimodality imaging of 209 non-IRAs. NIRS detected 299 LRPs. Of those, 41% showed a maxLCBI4mm <250, 39% a maxLCBI4mm 251-399, and 19% a maxLCBI4mm ≥400. LRPs with a maxLCBI4mm ≥400, as compared with LRPs with a maxLCBI4mm 250-399 and <250, were more frequently thin-cap fibroatheroma (TCFA) (42.1% vs. 5.1% and 0.8%; P < 0.001) with a smaller minimum FCT (80 μm vs. 110 μm and 120 μm; P < 0.001); a higher IVUS-derived percent atheroma volume (53% vs. 53% and 44%; P < 0.001) and a higher remodelling index (1.08 vs. 1.02 and 1.01; P < 0.001). MaxLCBI4mm correlated with OCT-derived FCT (r = 0.404; P < 0.001) and was the best predictor for TCFA with an optimal cut-off value of 401 (area under the curve = 0.882; P < 0.001).
CONCLUSION: LRPs with increasing maxLCBI4mm exhibit OCT and IVUS features of presumed plaque vulnerability including TCFA morphology, increased plaque burden, and positive remodelling. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Coronary artery disease; Intravascular imaging; Lipid-rich plaque; Plaque vulnerability; maxLCBI4mm

Mesh:

Substances:

Year:  2021        PMID: 31990323     DOI: 10.1093/ehjci/jez318

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  3 in total

Review 1.  Enhanced medical diagnosis for dOCTors: a perspective of optical coherence tomography.

Authors:  Rainer Leitgeb; Fabian Placzek; Elisabet Rank; Lisa Krainz; Richard Haindl; Qian Li; Mengyang Liu; Marco Andreana; Angelika Unterhuber; Tilman Schmoll; Wolfgang Drexler
Journal:  J Biomed Opt       Date:  2021-10       Impact factor: 3.758

2.  Predictors of Near-Infrared Spectroscopy-Detected Lipid-Rich Plaques by Optical Coherence Tomography-Defined Morphological Features in Patients With Acute Coronary Syndrome.

Authors:  Eisuke Usui; Taishi Yonetsu; Mari Ohmori; Yoshinori Kanno; Masahiko Nakao; Takayuki Niida; Yuji Matsuda; Junji Matsuda; Tomoyuki Umemoto; Toru Misawa; Masahiro Hada; Masahiro Hoshino; Yoshihisa Kanaji; Tomoyo Sugiyama; Tsunekazu Kakuta; Tetsuo Sasano
Journal:  Front Cardiovasc Med       Date:  2022-02-21

3.  Lipid-rich Plaques Detected by Near-infrared Spectroscopy Are More Frequently Exposed to High Shear Stress.

Authors:  Eline M J Hartman; Giuseppe De Nisco; Annette M Kok; Ayla Hoogendoorn; Adriaan Coenen; Frits Mastik; Suze-Anne Korteland; Koen Nieman; Frank J H Gijsen; Anton F W van der Steen; Joost Daemen; Jolanda J Wentzel
Journal:  J Cardiovasc Transl Res       Date:  2020-10-09       Impact factor: 4.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.